KK2-

The problems are two-fold. First cell studies do not accurately reproduce the situation in vivo, and secondly, animals differ in their biochemistry, immunology, tissue structure, and many other ways from us humans. So many drugs fail at the clinical level because they are not as effective for one reason or another, or because they produce adverse effects that were not seen in the animals. Having said that, apabetalone has a few things in its favour. We know it was safe in BETonMACE. We know that it had metabolic effects in humans in BETonMACE. And there are two potential mechanisms for an effect on the virus. All that's good, but it's not possible to give the chances of success, except in my view to say they're probably better than average.